Physician profile
Elizabeth Smith
NPI 1740896448
$5,800.38
in general payments reported to CMS, 2019-2025
55 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,053 · 2022: $2,351 · 2023: $282 · 2024: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $297 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $296.51 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $573.58 | 2021-2023 | |
| Janssen Biotech, INC. | $540.67 | 2021-2024 | Tecvayli, Darzalex, Imbruvica |
| Takeda Pharmaceuticals U.S.A., INC. | $431.95 | 2021-2023 | Iclusig |
| Astellas Pharma US INC | $400.31 | 2021-2023 | |
| Incyte Corporation | $348.83 | 2021-2022 | |
| Amgen INC. | $327.66 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $229.96 | 2021-2022 | |
| Seagen INC. | $218.06 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $212.45 | 2021-2022 | |
| Genzyme Corporation | $166.08 | 2021-2022 | |
| Global Blood Therapeutics, INC. | $143.83 | 2021-2022 | |
| Celgene Corporation | $137.35 | 2021-2023 | Pomalyst |
| Myovant Sciences INC. | $130.25 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $126.52 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.17 | 2021-2022 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.